Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rising Rupee Cuts Into Nicholas Piramal Revenues

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Mumbai-based Nicholas Piramal has lowered its revenue forecast in the current financial year because of rapid gains by the rupee against the dollar and pledged to cut low-margin products from its portfolio to ensure net profit would meet target

You may also be interested in...

Nicholas Piramal India Inks R&D Deal With Merck

Mumbai-based Nicholas Piramal India Limited inked a research and development deal with Delhi-based Merck subsidiary MSD Pharmaceuticals, NPIL announced Nov. 19

Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million

Lilly's research and development agreement with India-based Nicholas Piramal India Limited gives the Indian firm the potential to earn $100 million in milestones and call-back payments, the firms said Jan. 12

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts